open access publication

Article, 2023

Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review

Adverse Drug Reaction Bulletin, ISSN 2159-7774, 0044-6394, Volume 339, 1, Pages 1315-1318, 10.1097/fad.0000000000000067


Baden, Christoffer Storm [1] Andersen, Jon Traerup 0000-0003-0169-1328 [1] [2] Christensen, Mikkel Bring 0000-0002-8774-1797 [1] [2] Gade, Christina [1] [2]


  1. [1] Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital
  2. [NORA names: Miscellaneous];
  3. [2] University of Copenhagen
  4. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD]


Summary As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.


adolescents, adults, adverse events, agonists, challenges, children, cost, events, global health challenge, glucagon-like peptide-1 receptor agonists, health, health challenges, health outcomes, healthcare, healthcare costs, impact, intervention, issues, lack, lack of studies, management, negative impact, obesity, outcomes, peptide-1 receptor agonists, pharmaceuticals, pharmacological interventions, population, potential, receptor agonists, review, risk, risk of type 2 diabetes, safety, safety of glucagon-like peptide-1 receptor agonists, study, treat obesity, type 2 diabetes, weight, weight management

Data Provider: Digital Science